Skip to main content
CVS
NYSE Trade & Services

CVS Health Q2 Earnings Surge: Net Income Nearly Triples on Strong Government Business

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Positive
Importance info
7
Price
$110.01
Mkt Cap
$133.232B
52W Low
$61.35
52W High
$110.68
52W Position info
79% above low
Off High info
at 52W high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

CVS sits 79% above its 52-week low of $61.35.

Summary

CVS Health reported Q2 2026 net income of $2.995 billion, nearly triple the prior year, as the Health Care Benefits segment rebounded sharply. The company also amended credit agreements, extending maturities to 2029–2031.


Key Events · Earnings and Guidance · CVS

  • Net Income Nearly Triples

    Driven by improved operating performance across all segments, Q2 2026 net income attributable to CVS Health rose to $2.979 billion, up from $1.021 billion in Q2 2025.

  • Health Care Benefits MBR Improves Sharply

    The medical benefit ratio fell to 87.4% from 89.9%, reflecting better Government business performance and the absence of a $471 million premium deficiency reserve recorded in the prior year.

  • Operating Income Doubles

    Consolidated operating income increased 97.5% to $4.703 billion, with the Health Care Benefits segment contributing $2.191 billion, up from $1.002 billion.

  • Credit Facilities Extended

    CVS Health amended three $2.5 billion revolving credit facilities, extending maturities to 2029, 2030, and 2031, with no borrowings outstanding under any facility as of June 30, 2026.


Analysis · CVS · Trade & Services

A sharp rebound in the Health Care Benefits segment propelled CVS Health's second-quarter net income to nearly triple, reaching $2.995 billion. The medical benefit ratio dropped 250 basis points to 87.4%, a reflection of better underwriting and the absence of prior-year premium deficiency reserves. Operating income improved across all segments, and the company reinforced its liquidity by extending three credit facilities to 2029–2031. The results mark a significant turnaround from a year ago, when legacy litigation charges and reserve builds weighed on earnings.

At the time of this filing, CVS was trading at $110.01 on NYSE in the Trade & Services sector, with a market capitalization of approximately $133.2B. The 52-week trading range was $61.35 to $110.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CVS - Latest Insights

CVS
Aug 05, 2026, 6:32 AM EDT
Filing Type: 8-K
Importance Score:
8
CVS
Aug 05, 2026, 6:30 AM EDT
Source: Reuters
Importance Score:
9
CVS
Aug 05, 2026, 6:25 AM EDT
Source: PR Newswire
Importance Score:
8
CVS
Aug 03, 2026, 7:33 AM EDT
Source: Wiseek News
Importance Score:
7
CVS
Jul 14, 2026, 2:49 PM EDT
Source: Dow Jones Newswires
Importance Score:
8